News
New NovaTears from AFT
AFT Pharmaceuticals has released a new product for “dry eye” based on patented EyeSol technology. NovaTears aims to treat the symptoms of Evaporative Dry Eye (increased tear evaporation) as well as aqueous deficiency, and has the same refractive index as water which means it does not cause blurred vision.
“This is truly innovative technology and we encourage pharmacists to get in touch with their AFT representative in order to make this technology available in their pharmacy,” said AFT founder Hartley Atkinson.
View another high quality product from AFT Pharmaceuticals with the education module on pain relief below.
Source: Pharmcydaily.com.au, Thursday 12 July 2018
